title: Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
abstract: Plasminogen activator inhibitor-1 (PAI-1) is the major specific inhibitor of tissue-type plasminogen activator (tPA) which mediates fibrin clot lysis through activation of plasminogen. Wild-type-PAI-1 (wPAI-1) is rapidly converted to the latent form (half-life of approximately 2 h) and loses its ability to inhibit tPA. We developed a very long half-life PAI-1 (VLHL PAI-1), a recombinant protein with a half-life >700 h compared with wPAI-1. In this study, VLHL PAI-1 was assessed for its ability to inhibit clot lysis in vitro. Clot formation was initiated in normal plasma supplemented with tPA by the addition of either tissue factor or human recombinant FVIIa. Clot lysis time, monitored turbidimetrically in a microtiter plate reader, was determined at various concentrations of wPAI-1 and VLHL PAI-1. Both wPAI-1 and VLHL PAI-1 caused a significant increase in clot lysis time, although the latter was somewhat less effective at lower concentrations. The VLHL PAI-1, but not wPAI-1, maintained its anti-fibrinolytic activity after preincubation overnight at 37 degrees. These studies demonstrate that VLHL PAI-1 is an effective inhibitor of fibrin clot degradation. Due to the high stability of VLHL PAI-1 compared with wPAI-1, this novel inhibitor of tPA-mediated fibrinolysis may have therapeutic applications for treating surgical and trauma patients when used directly or in conjunction with the procoagulant recombinant FVIIa.
authors.affiliation: Urology Research Center, Health Science Campus, University of Toledo, Toledo, OH 43614-5807, USA. jerzy.jankun@utoledo.edu
authors.forename: Jerzy
authors.initials: J
authors.lastname: Jankun
authors.forename: Ansari M
authors.initials: AM
authors.lastname: Aleem
authors.forename: Steven H
authors.initials: SH
authors.lastname: Selman
authors.forename: Ewa
authors.initials: E
authors.lastname: Skrzypczak-Jankun
authors.forename: Wieslawa
authors.initials: W
authors.lastname: Lysiak-Szydlowska
authors.forename: Nicholas
authors.initials: N
authors.lastname: Grafos
authors.forename: Hugh J L
authors.initials: HJ
authors.lastname: Fryer
authors.forename: Robert S
authors.initials: RS
authors.lastname: Greenfield
mesh_terms: D001777:Blood Coagulation / Q000187:drug effects*; D004591:Electrophoresis, Polyacrylamide Gel; D005337:Fibrin / Q000378:metabolism*; D005342:Fibrinolysis / Q000187:drug effects*; D006207:Half-Life; D006801:Humans; D017395:Plasminogen Activator Inhibitor 1 / Q000302:isolation & purification / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology*; D013053:Spectrophotometry; D013816:Thermodynamics; D010959:Tissue Plasminogen Activator / Q000494:pharmacology*
chemical_list: D017395:Plasminogen Activator Inhibitor 1; D011994:Recombinant Proteins; D005337:Fibrin; D010959:Tissue Plasminogen Activator